Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca Sells 58,185 Shares of Company Stock

Merck & Co., Inc. (NYSE:MRK – Get Free Report) EVP Richard Deluca sold 58,185 shares of the stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the transaction, the executive vice president owned 112,955 shares of the company’s stock, valued at approximately $16,718,469.55. This represents a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Merck & Co., Inc. Trading Down 2.2%

NYSE:MRK traded down $3.27 during trading hours on Monday, reaching $144.49. 8,320,922 shares of the stock were exchanged, compared to its average volume of 10,544,569. The company has a market capitalization of $356.20 billion, a price-to-earnings ratio of 148.96, a PEG ratio of 6.77 and a beta of 0.13. Merck & Co., Inc. has a twelve month low of $92.11 and a twelve month high of $156.92. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11. The business has a 50-day moving average of $146.16 and a two-hundred day moving average of $128.61.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. The company had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. Merck & Co., Inc.’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.58 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 2.82 EPS for the current year.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Modern Wealth Management LLC raised its stake in Merck & Co., Inc. by 3.9% in the third quarter. Modern Wealth Management LLC now owns 56,221 shares of the company’s stock valued at $8,170,000 after purchasing an additional 2,086 shares in the last quarter. Utah Retirement Systems boosted its position in shares of Merck & Co., Inc. by 0.3% during the 3rd quarter. Utah Retirement Systems now owns 376,820 shares of the company’s stock worth $54,756,000 after purchasing an additional 1,193 shares in the last quarter. Integral Health Asset Management LLC grew its holdings in shares of Merck & Co., Inc. by 28.6% during the third quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company’s stock valued at $65,390,000 after buying an additional 100,000 shares during the last quarter. Elefante Mark B lifted its position in shares of Merck & Co., Inc. by 4.2% during the third quarter. Elefante Mark B now owns 5,000 shares of the company’s stock valued at $727,000 after purchasing an additional 200 shares in the last quarter. Finally, Elequin Capital LP purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter worth about $64,000. Institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on MRK shares. Scotiabank raised their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a report on Tuesday, September 29th. The Goldman Sachs Group boosted their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, August 21st. UBS Group lifted their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Finally, HSBC boosted their price objective on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $155.74.

Check Out Our Latest Research Report on MRK

About Merck & Co., Inc.

(Get Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Further Reading

Insider Buying and Selling by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.